Study of Calcium-phosphate Complications Induced by the Administration of IV Iron Supplementation in Patients With Rendu-Osler Disease

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case reports in the literature. Hypophosphatemia in this context is attributed to an excess of FGF-23 (defect of degradation linked to carbohydrates in martial preparations) with renal leakage of phosphate. Rendu-Osler disease (ROM) is an autosomal dominant genetic disease, favoring the formation of vascular malformations, including nasal and digestive telangiectasias causing repeated bleeding, even hemorrhages. Iron deficiency is frequent and profound there, and oral martial treatments are often insufficient to compensate for these losses. Regular iron infusions, to avoid transfusions, are often necessary.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Major subject (≥ 18 years old)

• suffering from Rendu-Osler disease and receiving IV iron supplementation

• Subject not objecting, after information, to the reuse of their data for scientific research purposes

Locations
Other Locations
France
Service de Médecine interne - CHU de Strasbourg - France
RECRUITING
Strasbourg
Contact Information
Primary
Murielle RONDEAU-LUTZ, MD
murielle.rondeau-lutz@chru-strasbourg.fr
33 3 69 55 10 13
Time Frame
Start Date: 2022-08-01
Estimated Completion Date: 2024-07-21
Participants
Target number of participants: 220
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov